Conversely, if these conditions are not met, vision can be very poor and unreliable. An eyewitness observation should be evaluated by an expert and its validity assessed. Environmental conditions that limit vision include: low lighting, movement, time constraints, distance, eye disease and other factors.
What is Jakafi? Jakafi (ruxolitinib) works by blocking certain enzymes in the body that affect blood cell production. Jakafi is used to treat myelofibrosis or polycythemia vera, which are bone marrow disorders that affect your body's ability to produce blood cells. Jakafi may also be used for purposes not listed in this medication guide.
The estimated US prevalence of MF in the US is ~18,000, most of whom are symptomatic to some extent. Annual cost of Jakafi is ~$92k. Assuming 9,000 receive treatment with a JAK inhibitor at an annual cost of $70k (patients may have treatment holidays), the addressable market is $630M. PV is much more prevalent (90,000 patients in the US) but it is typically milder and the unmet need is lower.